Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.610
-0.130 (-7.47%)
At close: Mar 6, 2026, 4:00 PM EST
1.630
+0.020 (1.25%)
After-hours: Mar 6, 2026, 7:59 PM EST
Ocugen Employees
Ocugen had 95 employees as of December 31, 2024. The number of employees increased by 30 or 46.15% compared to the previous year.
Employees
95
Change (1Y)
30
Growth (1Y)
46.15%
Revenue / Employee
$46,453
Profits / Employee
-$714,168
Market Cap
527.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 95 | 30 | 46.15% |
| Dec 31, 2023 | 65 | -19 | -22.62% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 41 | 273.33% |
| Dec 31, 2020 | 15 | -1 | -6.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| MeiraGTx Holdings | 409 |
| Vor Biopharma | 154 |
| Alpha Tau Medical | 125 |
| enGene Holdings | 82 |
| Larimar Therapeutics | 65 |
| Design Therapeutics | 55 |
| Forte Biosciences | 16 |
OCGN News
- 3 days ago - Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 5 days ago - Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - GlobeNewsWire
- 26 days ago - Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering - Benzinga
- 6 weeks ago - Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript - Seeking Alpha